Shopping Cart
Remove All
Your shopping cart is currently empty
Ro5-3335
Copy Product Info
😃Good
Catalog No. T4687Cas No. 30195-30-3
Alias Ro 5-3335, CBFβ-Runx1 inhibitor II
Ro5-3335 (CBFβ-Runx1 inhibitor II) is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 μM). Ro5-3335 represses RUNX1/CBFβ-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ. Ro5-3335 also reduces the leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. It also is a Tat antagonist and inhibits HIV-1 replication in vitro.
Ro5-3335
Copy Product Info😃Good
Purity: 99.87%
Catalog No. T4687Alias Ro 5-3335, CBFβ-Runx1 inhibitor IICas No. 30195-30-3
Ro5-3335 (CBFβ-Runx1 inhibitor II) is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 μM). Ro5-3335 represses RUNX1/CBFβ-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ. Ro5-3335 also reduces the leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. It also is a Tat antagonist and inhibits HIV-1 replication in vitro.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | In Stock | In Stock | |
| 5 mg | $97 | In Stock | In Stock | |
| 10 mg | $139 | In Stock | In Stock | |
| 25 mg | $272 | In Stock | In Stock | |
| 50 mg | $455 | In Stock | In Stock | |
| 100 mg | $596 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $96 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.87%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information
Product Introduction
Ro5-3335 AI Summary
Ro5-3335 exhibits a variety of bioactivities, including the inhibition of HIV-1 replication, with IC50 values of 600.0 nM in H9 cells and 4000.0 nM in SW480 cells. It also inhibits the Tat-induced HIV1 LTR transactivation with an IC50 value of 100.0 nM and the nuclear regulatory protein Tat with an IC50 value of 4000.0 nM. The compound has a therapeutic index of 5.9 as determined by a whole cell assay. Beyond HIV-1, Ro5-3335 shows various other biological activities, such as acting as a modulator of miRNAs, inhibitor of the Menin-MLL interaction in MLL-related leukemias, BAZ2B inhibition, ELG1-dependent DNA repair inhibition, delayed death inhibition of the malarial parasite plastid, and uPA inhibition on cell surfaces. It also blocks the interaction between CBF-beta and RUNX1 for Acute Myeloid Leukemia treatment, induces DNA re-replication in colon adenocarcinoma cells, reduces ATXN expression, functions as a GLP-1 receptor inverse agonist, stimulates the gsp mutation responsible for Fibrous Dysplasia/McCune-Albright Syndrome, inhibits human tyrosyl-DNA phosphodiesterase 1 both without and with CPT, and inhibits AMA1-RON for antimalarial development. Moreover, it displays antibacterial activity against Klebsiella pneumoniae MDR, Staphylococcus aureus MRSA, and Acinetobacter baumannii, and exerts antifungal effects against Candida albicans and Cryptococcus neoformans, though the latter efficacy is relatively low..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Ro5-3335 (CBFβ-Runx1 inhibitor II) is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 μM). Ro5-3335 represses RUNX1/CBFβ-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ. Ro5-3335 also reduces the leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. It also is a Tat antagonist and inhibits HIV-1 replication in vitro. |
| Targets&IC50 | CBF:1.1 μM |
| Synonyms | Ro 5-3335, CBFβ-Runx1 inhibitor II |
| Molecular Weight | 259.69 |
| Formula | C13H10ClN3O |
| Cas No. | 30195-30-3 |
| Smiles | Clc1ccc2NC(=O)CN=C(c3ccc[nH]3)c2c1 |
| Relative Density. | 1.46g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (231.04 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ro5-3335 | purchase Ro5-3335 | Ro5-3335 cost | order Ro5-3335 | Ro5-3335 chemical structure | Ro5-3335 formula | Ro5-3335 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.